Insider Sales Temper Rally in Pulse Biosciences Shares

Pulse Biosciences, a prominent biotechnology firm, experienced significant volatility as a wave of insider selling activity followed a period of substantial gains. The stock had surged more than 27% in a strong weekly performance before momentum was checked by transactions from a key company executive. This development has investors questioning the sustainability of the recent advance.

The company’s fundamental outlook received a major boost on September 8, when the U.S. Food and Drug Administration (FDA) granted critical Investigational Device Exemption (IDE) approval for its NANOCLAMP AF study. This global clinical trial, targeting the treatment of atrial fibrillation in 136 patients, represents a crucial milestone for the company’s proprietary Nanosecond Pulsed Field Ablation technology. Market analysts maintain positive coverage, with several reiterating buy recommendations and price targets as high... Read more...